Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|NBE-002||NBE002|NBE 002|iADC NBE-002|Anti-ROR1/PNU-159682 Derivative ADC NBE-002||ROR1 Antibody 3||NBE-002 is a next-generation antibody drug conjugate consisting of a humanized monoclonal antibody directed against the receptor tyrosine kinase ROR1, site-specifically conjugated to a derivative of the highly potent anthracycline PNU-159682, potentially leading to inhibition of DNA replication and repair and may inhibit tumor cell proliferation and survival (Cancer Research, 79(13), LB-197, doi: 10.1158/1538-7445.AM2019-LB-197).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04441099||Phase Ib/II||NBE-002||NBE-002 in Patients With Advanced Solid Tumors||Active, not recruiting||USA||0|